Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Inclusion Criteria: * Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective * Eastern Cooperative Oncology Group (ECOG) performance status \</= 2 * Life expectancy greater than 3 months * Adequate organ and marrow function * Written informed consent * Use of acceptable methods of contraception during the course of the study and for 3 months after completion of study * In the MTD expanded cohort: at least 20 subjects with metastatic and/or advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical resection with measurable disease as defined by RECIST Exclusion Criteria: * Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin C within 6 weeks) before the first scheduled dose of XL184 * Administration of an investigational drug within 30 days of the first dose of XL184 * Subject has not recovered from adverse events due to investigational agents or other medications administered more than 4 weeks before study enrollment * Known brain metastases * Uncontrolled intercurrent illness * Pregnancy or breastfeeding * Known HIV positive * Known allergy or hypersensitivity to any of the components of the XL184 formulation